Stocks Actavis Inc

More

  • Pfizer easily beat Wall Street expectations as the biggest U.S. drugmaker's first-quarter net income jumped 27 percent due to higher sales, lower taxes and one-time gains. Four weeks after dropping its record $160 billion deal to buy fellow drugmaker Allergan Plc and move its headquarters on paper to Ireland to reduce its taxes, New York- based Pfizer Inc....

  • Just weeks after the collapse of Pfizer's controversial deal to buy fellow drugmaker Allergan and move its headquarters to Ireland, company executives faced sharp criticism from shareholders at their annual meeting. Rules issued by the U.S. Treasury Department on April 5 eliminated most of the Allergan deal's financial incentives and forced New York-...

  • LONDON— With global economic growth slowing, inflation staying low and digital innovation generating uncertainty, companies are increasingly looking at partnership deals with other firms, even competitors, to boost revenues, consulting firm EY said Monday. In its half-yearly review of corporate deal-making, EY found that 40 percent of firms plan to enter...

  • LONDON— With global economic growth slowing, inflation staying low and digital innovation generating uncertainty, companies are increasingly looking at partnership deals with other firms, even competitors, to boost revenues, consulting firm EY said Monday. In its half-yearly review of corporate deal-making, EY found that 40 percent of firms plan to enter...

  • BOSTON, Dec 31- Billionaire investor William Ackman said on Thursday he sold about 5 million shares in drug company Valeant International in order to generate a tax loss as investors in his Pershing Square Capital Management face the biggest loss in the company's history. Pershing Square sold shares in its two on-shore portfolios in order to generate a tax...

  • Dec 22- Celgene Corp said it would allow for the sale of a generic version of its flagship multiple myeloma drug, Revlimid, in the United States over a year before patents covering the drug expire. The company said it would provide India- based Natco Pharma Ltd and its U.S. partner, Arrow International Limited, a unit of Allergan Plc, the license to Celgene's patents...

  • While the number of announced deals globally declined from 2014 by 2.1 percent to 39,687, deal volume rose 40.8 percent to a record $4.6 trillion, according to preliminary Thomson Reuters data, as big companies pursued their dream matches. This year's mega deals included many with long-expected operational efficiencies, such as brewer Anheuser-Busch...

  • *Zoetis, Pfizer assets could attract Bayer in future. Possible targets for the German company could include veterinary drug firm Zoetis and Pfizer's consumer health business, the two sources said. Bayer, Zoetis and Pfizer declined to comment.

  • NEW YORK, Dec 14- The tax-free treatment of the spin-offs Dow Chemical Co and DuPont plan to carry out after they merge their businesses is a prime driver of the deal, potentially saving tens of billions of dollars, industry experts said. The $120 billion merger, announced last week, comes less than a month after drug maker Pfizer Inc said it would use its $160 billion...

  • Democratic presidential candidate Hillary Clinton detailed plans on Wednesday to crack down on companies that shift profits overseas, a practice known as earnings stripping. As an example, she cited the $160 billion plan by U.S. pharmaceutical maker Pfizer Inc to purchase smaller rival Allergan Plc and move its headquarters to Ireland.

  • WATERLOO, Iowa, Dec 9- U.S. Democratic presidential candidate Hillary Clinton will continue her push to crack down on companies that shift profits overseas, at a campaign stop on Wednesday in Iowa, where she will unveil her plan to rein in the practice, known as earnings stripping. Clinton and her campaign have made clear they are viewing the real-life...

  • Clinton will call for spending the revenue raised by her proposed tax to boost manufacturing jobs in the United States, the Associated Press reported. Pfizer Inc last month announced it would buy Allergan Plc in a deal worth $160 billion in part to slash its U.S. tax bill. The purchase-- an example of a huge inversion deal-- would create the world's largest drugmaker...

  • *Guggenheim named Pfizer's lead adviser on $160 bln Allergan deal. *Schwartz has cultivated ties with Pfizer and its CEO over years. His strategy paid off handsomely when Guggenheim was named lead adviser for one of the biggest deals in history- Viagra-maker Pfizer's $160 billion acquisition of Botox-maker Allergan.

  • Nov 25- Allergan PLC said on Wednesday it will not appeal to the U.S. Supreme Court a court ruling this year that blocked the company from discontinuing its top-selling Alzheimer's drug in favor of a pricier version. Allergan will also pay $172,000 in legal expenses under a settlement with New York Attorney General Eric Schneiderman, who filed an antitrust...

  • *Global security concerns also remained on the forefront after the U.S. State Department issued a global travel alert for Americans and Turkey said it shot down a Russian warplane that had violated its airspace near the Syrian border. Shares of travel website operator Priceline were down 1.8 percent, while cruise operators Carnival Corp and Royal Carribean...

  • *Pfizer-Allergan deal fails to inspire Wall Street investors. TOKYO, Nov 24- Asian shares struggled on Tuesday after a healthcare mega-merger failed to impress Wall Street, while the dollar took a breather from its run to 8- month highs on rising convictions that the Federal Reserve will raise interest rates next month. "We're post Japan Inc earnings now and the...

  • WASHINGTON, Nov 23- U.S. politicians condemned Pfizer Inc's deal with Allergan Plc as a tax dodge on Monday, bringing another round of hand-wringing in Washington over the corporate tax code, though legislative action before 2017 is unlikely. Democrats heaped the most criticism on the New York- based drug maker, with Hillary Clinton accusing Pfizer of using...

  • TOKYO, Nov 24- Asian shares dragged their feet on Tuesday after a healthcare mega-merger failed to impress investors while the dollar held firm near an eight-month high as investors grew more convinced of a U.S. rate hike next month. MSCI's broadest index of Asia-Pacific shares outside Japan was almost flat while Japan's Nikkei dipped 0.1 percent after a long...

  • Nov 23- Activist investor Bill Ackman's hedge fund has significantly increased its investment in Valeant Pharmaceuticals International, and signaled it may play a greater role in the beleaguered drugmaker's strategy, according to a regulatory filing. Ackman's Pershing Square Capital Management raised its stake in Valeant to 9.9 percent from 5.7 percent...

  • WASHINGTON, Nov 23- U.S. politicians condemned Pfizer Inc's deal with Allergan Plc as a tax dodge on Monday, bringing another round of hand-wringing in Washington over the corporate tax code, though legislative action before 2017 is unlikely. Democrats heaped the most criticism on the New York- based drug maker, with Hillary Clinton accusing Pfizer of using...